AT THE START
What are we starting from?
Establish a molecular baseline at diagnosis or the start of monitoring to compare with future blood draws.
CANOS ONCOTRACK · NOW AVAILABLE
Know how their
cancer is changing.
Methylation-based cancer monitoring.
From a simple blood draw.
Canos OncoTrack reads cancer-associated DNA methylation in blood to track treatment response, look for residual disease and follow changes over time. Precision care for your dog, powered by epigenetics.
Regular price $499Offer price $299 · For dogs diagnosed with cancer
MORE UNDERSTANDING. MORE MOMENTS TOGETHER.THROUGH TREATMENT. INTO FOLLOW-UP.
Follow the signal.
Through every stage.
Follow molecular changes across blood draws, alongside your dog’s examinations, scans and symptoms.
THE VALUE OF REPEATED MEASUREMENTS
Establish a starting point.
Follow what changes.
DURING TREATMENT
Is the cancer signal changing?
See whether cancer-associated signals fall, persist or increase during treatment.
AFTER TREATMENT
Is there a signal to follow up?
Look for minimal residual disease (MRD) after treatment and track signals that return during follow-up.
METHYLATION-BASED LIQUID BIOPSY
Cancer changes DNA.
And the marks it carries.
Methylation is a layer of chemical marks on DNA that helps control how cells work. Cancer changes these patterns. When cells release DNA into the blood, those marks travel with it. OncoTrack reads this epigenetic signal in cell-free DNA (cfDNA).
A wider field of signals
Cancer alters methylation across many regions of DNA, creating a broad set of signals to read alongside genetic mutations.
Reach beyond mutations
Methylation-based assays have detected tumour DNA in blood samples where somatic mutations were not detectable.
Measure change over time
Repeated methylation measurements track the amount of tumour-derived DNA in blood, revealing molecular changes through treatment and follow-up.
Methylation is central to OncoTrack. Canos integrates this readout with DNA fragment patterns and genome-wide changes.
THE TEST, AT A GLANCE
A blood sample.
A view across visits.
- Who it’s for
- Dogs diagnosed with cancer, during treatment or follow-up.
- Sample
- A blood draw arranged with your veterinary team.
- Technology
- Cell-free DNA analysis with methylation, fragment and genomic signals.
- What you see
- Cancer-associated signal status, estimated tumour fraction and changes across visits.
- Clinical context
- Results read with treatment dates, examination findings and imaging.
METHYLATION IN HUMAN CANCER CARE
A stronger signal.
Measured in blood.
Human studies show methylation detecting tumour DNA beyond mutations, identifying residual disease and tracking treatment response.
GUARDANT INFINITY · AACR RESEARCH POSTER · 2023
More cancer signals detected.
In 5,045 human colorectal, lung and breast cancer samples, methylation analysis detected ctDNA in 90%. Somatic mutations were detectable in 64%.
Methylation90%
Somatic mutations64%
GUARDANT REVEAL · CLINICAL CANCER RESEARCH · 2024
Find residual disease after surgery.
In a study of 342 people with resected colorectal cancer, a methylation-based assay identified recurrence with a median lead time of 5.3 months. Longitudinal sensitivity was 81% in stage II or higher colon cancer; specificity was 98.2% across 1,461 post-treatment samples.
Read the MRD studyRADIOHEAD · CANCER RESEARCH COMMUNICATIONS · 2025
Read treatment response earlier.
Among 627 people with advanced cancers receiving immunotherapy, changes in methylation-based tumour fraction were associated with survival. Molecular non-response preceded clinical progression in 209 patients, by a median of 3.03 months.
Read the treatment monitoring studyCANINE RESEARCH. MOLECULAR INSIGHT.
Built on evidence.
Built for dogs.
Blood-based studies in dogs have tracked tumour DNA after surgery, through treatment and at recurrence.
AMERICAN JOURNAL OF VETERINARY RESEARCH · 2024
Seeing recurrence
in the blood.
The study documented cancer signals in blood before clinical recurrence, supporting molecular monitoring during follow-up.
Read the canine monitoring studySCIENTIFIC REPORTS · 2022
Molecular change after surgery.
In dogs with malignant splenic tumours, estimated tumour DNA fractions fell after surgery.
Read the studyRCVS KNOWLEDGE · 2025
A veterinary evidence collection.
Research on liquid biopsy for cancer detection, treatment monitoring and recurrence, brought together for veterinary teams.
Explore the evidenceCANOS BIOINFORMATICS · 2026
More information from the same blood DNA.
Canos bioinformatics combines methylation, fragment lengths and genomic patterns to detect cancer signals and track changes over time.
CANCER-DETECTION CROSS-VALIDATION
- Sensitivity
- 90.6%
- Specificity
- 95.1%
- Negative predictive value
- 87.3%
- Plasma sequencing runs
- 896
SAMPLE REPORT
See how the signal changes.
Follow a lymphoma monitoring series from diagnosis through treatment and follow-up.
View sample reportDownload a copyCANINE cfDNA MRD MONITORING · PATIENT C-014 · LYMPHOMA
T4 · 7 Sep 2026
Signal detected
Estimated tumour fraction 7.6%
Cancer-associated signal detected again at week 20.
ORDER CANOS ONCOTRACK
Your dog. Your vet.
Our team, alongside you.
Order OncoTrack and choose your blood draw preference. Our team works with your vet to plan monitoring around your dog’s treatment and follow-up.
Regular price $499Offer price $299 · Treatment and relapse monitoring
Order your test
Choose OncoTrack in the order form. Book a free consultation if you’d like to talk first.
Arrange the blood draws
Choose a mobile vet, your own vet or our group draw day. We plan follow-up draws with your veterinary team.
Follow the results together
Results arrive about 1–2 weeks after your appointment. Our team reviews the report with your vet.
